ContraVir Pharmaceuticals to Present at NobleCon14

ContraVir Pharmaceuticals to Present at NobleCon14

January 23, 2018

EDISON, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at NobleCon14 – Noble Financial Capital Market’s Fourteenth Annual Investor Conference to be held January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida.

James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

A high-definition, video webcast of the presentation will be available the following day on the company's website http://ir.contravir.com/index.php/events-and-presentations and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV, recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and invivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com.

For further information, please contact:

Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028

Primary Logo

Source: ContraVir Pharmaceuticals Inc